Jefferies Financial Group Reiterates Buy Rating for Haleon (LON:HLN)

Haleon (LON:HLN)‘s stock had its “buy” rating reissued by analysts at Jefferies Financial Group in a report released on Wednesday, Marketbeat reports. They presently have a GBX 450 target price on the stock. Jefferies Financial Group’s price target indicates a potential upside of 19.02% from the company’s previous close.

A number of other equities analysts have also recently issued reports on HLN. JPMorgan Chase & Co. increased their price target on Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a report on Wednesday, November 26th. Berenberg Bank increased their target price on shares of Haleon from GBX 507 to GBX 517 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a research note on Friday, October 31st. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 407.83.

Haleon Stock Up 0.2%

Shares of Haleon stock opened at GBX 378.10 on Wednesday. Haleon has a one year low of GBX 325.10 and a one year high of GBX 419.50. The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93. The stock’s 50-day moving average is GBX 368.56 and its 200 day moving average is GBX 359.32. The firm has a market cap of £33.67 billion, a price-to-earnings ratio of 22.64, a PEG ratio of 1.49 and a beta of 0.19.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.